Morgan Stanley Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $18.00

REGENXBIO (NASDAQ:RGNX) had its target price decreased by Morgan Stanley from $25.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on the stock. Barclays began coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price target for the company. UBS Group reaffirmed an “overweight” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Tuesday. The Goldman Sachs Group reduced their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday. Royal Bank Of Canada raised their price target on REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Wall Street Zen cut REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.80.

REGENXBIO Trading Down 1.8%

Shares of NASDAQ RGNX opened at $8.35 on Tuesday. The business has a 50-day moving average of $13.18 and a 200-day moving average of $11.39. The firm has a market capitalization of $422.68 million, a price-to-earnings ratio of -2.41 and a beta of 1.05. REGENXBIO has a 12 month low of $5.03 and a 12 month high of $16.19.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently modified their holdings of RGNX. JPMorgan Chase & Co. grew its position in REGENXBIO by 4.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock worth $38,959,000 after acquiring an additional 185,223 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of REGENXBIO by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company’s stock valued at $48,588,000 after purchasing an additional 36,042 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of REGENXBIO by 64.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock valued at $16,709,000 after purchasing an additional 454,977 shares during the period. Geode Capital Management LLC grew its holdings in shares of REGENXBIO by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,145,206 shares of the biotechnology company’s stock worth $16,495,000 after purchasing an additional 19,658 shares during the last quarter. Finally, Integral Health Asset Management LLC increased its stake in shares of REGENXBIO by 57.1% in the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $10,615,000 after buying an additional 400,000 shares during the period. Institutional investors own 88.08% of the company’s stock.

More REGENXBIO News

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Clear Street argues there’s still large upside to RGNX despite the FDA pushback, offering a bullish take that could attract speculative buyers. Regenxbio stock still has over 300% upside despite FDA pushback on Hunter syndrome drug: Clear Street
• Neutral Sentiment: HC Wainwright kept a “Buy” rating and a $32 price target on RGNX, which may reduce some downside pressure by signaling conviction from at least one equity research shop. MarketBeat REGENXBIO coverage
• Negative Sentiment: The U.S. Food & Drug Administration declined to approve REGENXBIO’s RGX-121 gene therapy for Hunter syndrome — the primary near-term catalyst — which directly undermines the company’s commercialization timeline and revenue prospects. US FDA rejection sends Regenxbio shares sharply lower
• Negative Sentiment: HC Wainwright sharply reduced Q3/Q4 and FY2026 EPS estimates for RGNX (moving quarterly forecasts from about ($0.22) to ($0.61) and cutting FY guidance), signaling weaker near-term financial outlook and increasing uncertainty around cash burn and financing needs. HC Wainwright research note
• Negative Sentiment: Chardan Capital lowered its expectations for RGNX, adding further sell-side skepticism and pressure on the stock’s sentiment. Chardan Capital Has Lowered Expectations for REGENXBIO
• Negative Sentiment: Investor litigation risk emerged — Pomerantz LLP opened an investigation into RGNX investors, which typically raises legal uncertainty and potential costs. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. – RGNX

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.